Milestone for RNAi therapeutics?
A company developing therapeutics using RNA interference (RNAi) today (February 29) linkurl:announced;http://phoenix.corporate-ir.net/phoenix.zhtml?c=148005&p=irol-newsArticle&ID=1113937&highlight= positive results of a clinical trial in humans ? marking a first for the much-touted promise of RNAi-based therapies. Alnylam, based in Cambridge, Mass., exposed 88 male volunteers to respiratory syncytial virus, which affects mostly young children and the elderly. Half of the subjects received the
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Meet the Author
Alla Katsnelson
This person does not yet have a bio.View full profile
Share
